Ryan Scott

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com

Articles

Rare Case Study of ALK+ Advanced RCC Highlights Drive for Personalized Medicine in Kidney Cancer

September 18th 2024

Alexandra Drakaki, MD, dives into a case study of a patient with ALK-positive RCC that exemplified the importance of NGS and precision medicine in kidney cancer.

Experts Highlight Top Findings From the 2024 IASLC World Conference on Lung Cancer

September 18th 2024

Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.

FDA Grants RMAT Designation to P-BCMA-ALL01 for R/R Multiple Myeloma

September 17th 2024

The FDA has granted regenerative medicine advanced therapy designation to P-BCMA-ALL01 for relapsed/refractory multiple myeloma.

Updated NCCN Kidney Cancer Guidelines Bring New Recommendations for Advanced Non–Clear Cell RCC

September 17th 2024

Bradley McGregor, MD, shared his insights on the updated NCCN Clinical Practice Guidelines in kidney cancer.

Belantamab Mafodotin Plus Vd Earns Breakthrough Therapy Designation in China for R/R Myeloma

September 17th 2024

China’s NMPA granted breakthrough therapy designation to belantamab mafodotin plus bortezomib and dexamethasone in relapsed/refractory myeloma.

Inavolisib Demonstrates Safety, Disease Control in PIK3CA-Mutated Solid Tumors

September 16th 2024

Inavolisib demonstrated a favorable safety profile and generated disease control in patients with tumors harboring PIK3CA mutations.

FDA Lifts Partial Clinical Hold on Trials Evaluating Azenosertib in Advanced Solid Tumors

September 16th 2024

The FDA has lifted the partial clinical hold previously placed on studies evaluating azenosertib in advanced solid tumors.

IMM-1-104 and Chemo Combination Elicit Responses in First-Line Pancreatic Cancer

September 13th 2024

First-line IMM-1-104 combined with modified gemcitabine/nab-paclitaxel elicited both partial and complete responses in patients with pancreatic cancer.

Cabozantinib/Nivolumab Combination Findings Further Inform RCC Care

September 13th 2024

Adam E. Singer, MD, PhD, highlights how cabozantinib and nivolumab treatment compares with other therapies in terms of efficacy and safety in RCC.

More Precise Classifications of Non–Clear Cell RCC Are Required to Improve Personalized Treatment

September 12th 2024

Alexandra Drakaki, MD, expands on the need to improve specific classifications in non–clear cell renal cell carcinoma.

Bel-Sar Generates Tumor Control, Preserves Visual Acuity in Early Choroidal Melanoma

September 12th 2024

First-line bel-sar displayed tumor control and preserved visual acuity in early-stage choroidal melanoma.

FDA Grants Orphan Drug Designation to Tebapivat for MDS

September 12th 2024

The FDA has granted orphan drug designation to tebapivat for the treatment of myelodysplastic syndromes.

Oral SERDs, PROTACs Could Add to Expanding ER+ Advanced Breast Cancer Arsenal

September 12th 2024

Komal Jhaveri, MD, FACP, discusses the emergence of oral SERDs and PROTACs in the treatment of estrogen receptor–positive advanced breast cancer.

Nuances of HER2 Expression Underscore Need for More Precise Testing in Breast Cancer

September 11th 2024

As more therapies emerge for HER2-positive, -low, or -negative breast cancer, pathologists highlight the need for more precise methods of evaluating HER2 expression.

FDA Grants Orphan Drug Designation to Elraglusib for Soft Tissue Sarcomas

September 11th 2024

The FDA has granted orphan drug designation to the novel GSK-3β inhibitor elraglusib for the treatment of patients with soft tissue sarcoma.

Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC

September 10th 2024

Tarlatamab demonstrated durable responses and long-term tolerability in patients with previously treated small cell lung cancer.

Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL

September 6th 2024

Treatment with valemetostat demonstrated activity and was tolerable in patients with relapsed/refractory peripheral T-cell lymphoma.

FDA Grants Fast Track Designation to VMT01 for Unresectable/Metastatic MC1R+ Melanoma

September 5th 2024

The FDA has granted fast track designation to the MCR1-targeted theranostic ligand VMT01 for unresectable or metastatic melanoma.

Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL

September 4th 2024

Tisagenlecleucel is moving to earlier lines of therapy for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Growth in the Multiple Myeloma Treatment Armamentarium Diversifies Treatment Strategies

September 2nd 2024

Rahul Banerjee MD, FACP, discusses how he decides between treatment approaches across subsets of patients with multiple myeloma.